Androgen receptor (AR) splice variants (SV) have been implicated in the development of metastatic castration-resistant prostate cancer and resistance to AR targeting therapies, including abiraterone and enzalutamide. Agents targeting AR-SV are urgently needed to test this hypothesis and further improve the outcome of patients suffering from this lethal disease. Clin Cancer Res; 22(17); 1–3. ©2016 AACR.
See related article by Yang et al., p. 4466
- Received May 26, 2016.
- Accepted May 26, 2016.
- ©2016 American Association for Cancer Research.